PharmaFocus Today – Page 137 – media

Innovent Biologics and Roche have reached a global exclusive licensing agreement for the new generation of DLL3 antibody conjugated drugs

On January 2, 2025, San Francisco, USA and Suzhou, China – Xinda Biopharmaceutical Group (hereinafter referred to as “Xinda Biopharmaceutical”), a biopharmaceutical company dedicated to the research and development, production, and sales of innovative drugs in major disease fields such as oncology, autoimmune, cardiovascular and metabolic, and ophthalmology, announced today that it has reached a global exclusive cooperation and licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to promote the development of IBI3009, a new generation of antibody coupled drug (ADC) candidate products targeting Delta like ligand 3 (DLL3), aiming to provide a new treatment option for patients with advanced small cell lung cancer (SCLC). IBI3009 has currently obtained clinical application (IND) approval in Australia, China, and the United States, and the first patient in phase I clinical trials will be administered in December 2024. IBI3009： Potential best in class DLL3 ADC candidate drugs IBI3009 specifically targets DLL3, an ...
- Source: drugdu
- 309
- January 4, 2025
The bill “failed”, WuXi Biologics is back

WuXi Biologics is back. Since the progress of the US Biosafety Act has continued to jump sideways, WuXi Biologics’ stock price performance has been suppressed before September. As the company’s stock price rose to more than 3% today and closed up 2.19%, it not only outperformed the Hang Seng Index and Hang Seng Medical ETF, but the company’s overall recent trend has continued to improve (a cumulative increase of 58.21% since September 2024). This is due to the fact that the negative shoe finally landed. According to the latest news from the US House of Representatives bill, the Biosafety Act was not included in the 2025 NDAA (National Defense Security Act), which objectively confirmed the failure of the bill’s rapid legislation. In addition, according to recent news, the 2025 Continuing Appropriations and Extension Act (CR Act) announced by the US Congress also did not include the Biosafety Act. WuXi Biologics ...
- Source: drugdu
- 343
- January 4, 2025
A major breakthrough in solid tumor CAR-T, the key clinical success of domestic CAR-T therapy in the treatment of gastric cancer

On the morning of December 30, Keji Pharmaceutical (02171.HK) announced that China’s pivotal Phase II clinical trial of Serigene Oronza Injection for the treatment of advanced gastric/esophagogastric junction adenocarcinoma has obtained preliminary positive results. ▍About Sulgid Oronza Injection According to the announcement, this trial is a randomized controlled, multi-center clinical trial conducted in China, aiming to evaluate the treatment of Shuruiji Olense Injection (CT041) in the treatment of advanced patients with positive Claudin18.2 expression who have failed at least 2 lines of treatment in the past. Efficacy and safety in gastric/esophagogastric junction adenocarcinoma. The trial achieved its primary endpoint of progression-free survival (PFS) as assessed by an independent review committee (IRC). There was a statistically significant improvement in progression-free survival among subjects in the Serigen-Olenza injection group compared with the investigator’s choice treatment group. Previous test data shows that the safety of this product is controllable. Shuregen Orenza Injection is ...
- Source: drugdu
- 547
- January 4, 2025
The chairman of the board of directors of the “first cancer early screening stock” was removed

Today, Nova Health, a leading company in the field of early cancer screening, has experienced major personnel changes. On December 31 (today), Nova Health announced that Mr. Zhu Yeqing has resigned as Chairman of the Board (“Chairman”) and Chief Executive Officer of the Company (“CEO”) on December 30, 2024 due to personal health reasons, effective from the same date (“Resignation”). At the same time, the announcement pointed out that the board of directors believes that Mr. Zhu Yeqing’s management style and philosophy are significantly different from those of other members of the board of directors, and allowing Mr. Zhu Yeqing to continue to participate in the management of the company is not in the overall best interests of the company and its shareholders. Given that Mr. Zhu Yeqing only resigned from the positions of Chairman and Chief Executive Officer, not the position of Executive Director, the board of directors has ...
- Source: drugdu
- 179
- January 4, 2025
“The world’s first” subcutaneous PD-1 is approved for marketing, covering 12 tumor types

On December 27, local time, the US FDA announced that it had approved Bristol-Myers Squibb’s “Nivolumab” subcutaneous injection (Opdivo Qvantig) for marketing, for the treatment of adult solid tumor indications previously approved for its intravenous injection Opdivo. This is the world’s first approved subcutaneous PD-1 inhibitor. ▍Approved indications The approved indications for subcutaneous injection of Nivolumab include renal cell carcinoma, melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal cancer, gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. Screenshot source: FDA official website Nivolumab is the world’s first approved PD-1 inhibitor. It has been approved for marketing in more than 65 countries and regions including the United States, the European Union, Japan and China, covering 12 tumor types, including lung cancer, head and neck cancer, gastric cancer, esophageal cancer, liver cancer, kidney cancer, colorectal cancer, urothelial carcinoma, melanoma, Hodgkin’s lymphoma, pleural ...
- Source: drugdu
- 367
- January 4, 2025
The market size of health products exceeds 300 billion, with silver haired and post-90s generations as the main consumers

According to the Statistical Bulletin on the Development of Civil Affairs in 2023, as of the end of 2023, the population of elderly people aged 60 and above in China will be close to 300 million, accounting for 21.1% of the total population. According to international standards, Chinese society has entered a stage of moderate aging. The deepening of aging population and the improvement of health awareness have become important factors in the rise of the health product market. Especially with the sinking and popularization of e-commerce channels, purchasing health products has become more convenient. While nurturing opportunities, the industry also harbors many consumer traps. Starting from multiple dimensions such as overall market size, category track, channel distribution, and consumer attributes, the New Beijing News reporter presents the current development status of the domestic health product industry from different perspectives, insights into consumer trends, and faces the opportunities and crises ...
- Source: drugdu
- 818
- January 3, 2025
priced higher than semaglutide, it is a self funded medication

Novo Nordisk’s strongest competitor, semaglutide, has officially been commercialized and launched in China. On December 25th, a reporter from The Paper noticed that several e-commerce platforms now offer diagnosis, treatment, and medication services for Eli Lilly’s glucose dependent insulinotropic polypeptide (GIP)/glucagon like peptide-1 (GLP-1) receptor agonist tilboptin (trade name: Mufengda). The indications of tilporide include diabetes and weight loss. At present, the prices of various businesses on the platform are different, and it is suggested that the specific price should be subject to the final selected store price. image Multiple e-commerce platforms offer the option to purchase Eli Lilly and its derivatives Taking an Internet hospital business as an example, the quotation of 0.5ml: 2.5mg * 4 pieces is 2480 yuan, and the single piece price is 620 yuan. The merchant claims that their drugs are authentic, quickly registered, and reserved for appointment. The reporter from Pengpai News contacted the ...
- Source: drugdu
- 719
- January 3, 2025
Billions! Nearly 20 machinery companies have completed a new round of financing

In December 2024, nearly 20 equipment companies worldwide completed a new round of financing, with a total amount exceeding 2 billion yuan. Among them, several domestic enterprises completed financing of billions of yuan in December. Chenxin Technology On December 3rd, Chenxin Technology announced the completion of a 200 million yuan Series B financing, led by Guotou Chuangye, with Sunshine Ronghui and old shareholder Huoshan Stone Investment following suit. This round of financing will mainly be used for the company’s forward-looking product research and development, new product mass production, and global business layout. Supplier of precision instruments and automated testing equipment for silicon carbide (SiC) power semiconductors. Chenxin Technology was established in 2020, and its main products cover the characterization and testing of power semiconductor devices based on silicon carbide (SiC), gallium nitride (GaN), and silicon (Si). Among them, in the field of high-end medical imaging equipment, Chenxin Technology focuses on ...
- Source: drugdu
- 467
- January 3, 2025
Two major pharmaceutical giants collaborate heavily!

On the morning of December 13th, Shiyao Group announced that it has entered into an exclusive authorization agreement with BeiGene for the development, manufacturing, and commercialization of the group’s new methionine adenosyltransferase 2A (MAT2A) inhibitor (SYH2039), as well as any subsequent drugs composed of or containing this compound worldwide. According to the agreement, Shiyao Group will receive a total advance payment of $150 million and has the right to receive up to $135 million in potential development milestone payments and up to $1.55 billion in potential sales milestone payments, as well as tiered sales bonuses calculated based on the annual net sales of the product. Excluding tiered sales commissions, the total amount of the above-mentioned cooperation is as high as 1.835 billion US dollars, which is approximately 13.3 billion yuan at the latest exchange rate. SYH2039 is a clinical candidate drug obtained by Shiyao Group through an AI driven small ...
- Source: drugdu
- 269
- January 3, 2025
$135 million! Domestic liraglutide is coming fiercely

Recently, Hanyu Pharmaceutical announced that its independently developed GLP-1 Liraglutide Injection has been approved by the FDA for marketing as the first generic version and has officially landed in the United States. As we all know, GLP-1 drugs have become the focus of the market in recent years due to their significant efficacy in reducing blood sugar and weight loss. However, precisely because of the skyrocketing demand, this type of drug has repeatedly faced problems of insufficient production and supply. The launch of Hanyu Pharmaceutical’s liraglutide generics in the U.S. market is not only an important breakthrough for Hanyu Pharmaceuticals in the international market, but also marks the imminent release of domestically produced liraglutide generics. Liraglutide is a human glucagon-like peptide-1 (GLP-1) analog that can activate human GLP-1 receptors, promote insulin secretion, inhibit glucagon secretion, delay gastric emptying, and Increases feelings of fullness, thereby lowering blood sugar and weight. Liraglutide ...
- Source: drugdu
- 1,034
- January 3, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.